Table 1 Characteristics and quality assessment of individual studies included in the meta-analysis
First author (Publication year) | Duration of study | Population | Disease severity | Median age (HSCT/IST) | Number of patients (HSCT/IST) | Donor | Stem cell source | Conditioning program | Prevention of GVHD | IST drugs | Follow-up time (HSCT/IST) | Selection/Comparability/Exposure | NOS Score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kojima et al. (2000) [11] | 1984–1998 | Children | SAA + VSAA + NSAA | 10 (0–16), 9 (1–17) | 37/63 | MRD | BM | Cy + TLI, Cy + ATG ± TLI, Cy + TLI + TBI | MTX + CsA, CsA | ATG/ALG + HD-Steroids, ATG + CsA | 89 (6–166), 82 (6–186); (Month) | ****/**/** | 8 |
Fouladi et al. (2000) [12] | 1987–1997 | Children | SAA | 8.8 (2.1–15.9), 9.8 (1.3–16.6) | 21/20 | MRD | BM | Cy + TBI and others | MTX + CsA, CsA, CsA + Pred | ATG ± CsA | 4.3 (3.3–6.7), 3 (0.2–6.7); (Year) | ***/**/** | 7 |
Choi et al. (2017) [13] | 1998–2012 | Children | SAA | 9.3 (0.6–17.2), 8.5 (1.3–14.1) | 23/19 | MUD | BM/PBSCs/CB | Flu + Cy ± TBI, Bu + Cy + ATG, Cy + TBI, Cy + ATG | MTX + CsA or Tac, CsA, others | ATG + CsA | NR | ***/**/** | 7 |
Cheng et al. (2017) | 2007–2016 | Children | SAA | 8 (2–17), 6 (4–16) | 28/24 | HID | BM + PBSCs | Bu + Cy + ATG | CSA + MTX + MMF | ATG + CsA | 37.9 (8.7–108.3), 54.8 (8.9–115.7); (Month) | ***/**/** | 7 |
Yoshida et al. (2014) [14] | 1992–2009 | Children | SAA | 11 (0–16), 9 (0–16) | 213/386 | MRD | BM | Cy ± Irradiation, CY + ATG ± Irradiation, Flu + Cy ± Irradiation, Flu + Cy + ATG ± Irradiation and others | MTX + CsA or Tac | ATG + CsA ± G-CSF | 101 (18–213), 106 (22–224); (Month) | ***/**/** | 7 |
Dufour et al. (2015) [15] | 2000–2009 | Children | SAA | NR | 396/167 | MRD | BM/PBSCs | Cy, Cy + Flu ± ATG and others | CsA + MTX | ATG + CsA | NR | ***/**/** | 7 |
Yang et al. (2019) [16] | 2012–2016 | Children | SAA | 13 (4–18), 12 (4–17) | 20/29 | HID | BM/PBSCs, BM + PBSCs | Cy + ATG ± Flu, Flu + Cy + Bu + ATG | CsA + MTX + MMF | ATG + CsA | NR | ***/**/** | 7 |
Xu et al. (2018) | 2009–2017 | Adult | SAA | 28 (18–49), 32 (18–62) | 28/32 | HID | BM + PBSCs | Bu + Cy + ATG | MTX + CsA + MMF | ATG + CsA | 24.7 (6.1–103), 20.2 (3.2–96.0); (For alive) (Month) | ***/**/** | 7 |
Ahn et al. (2003) [17] | 1990–2001 | Adult | SAA | 28 (14–43), NR | 64/156 | MRD | BM | Cy + ATG, Cy + TLI | MTX + CsA, CsA | ATG + CsA, ATG + HD-Steroids, CsA | NR | ***/**/** | 7 |
Kim et al. (2003) [18] | 1990–1999 | Adult | SAA | 22 (14–43), 34 (15–75) | 22/74 | MRD | BM | Cy + TBI, Cy + ATG, Bu + Cy | MTX + CsA | ATG/ALG, ATG + CsA | NR | ***/**/** | 7 |
Ellis et al. (2002) [19] | 1977–1999 | Adult + Children | SAA | 22 (6–59), 55 (9–78) | 15/16 | MRD | BM | Cy ± Irradiation | MTX, MTX + CsA | ATG, ATG + CsA | 4.3 (0.2–242.2), 52.5 (1.1–165.4); (Month) | ***/**/** | 7 |
Ghavamzadeh et al. (2004) [20] | 1990–2001 | Adult + Children | SAA | 19, 25 (Mean) | 29/24 | MRD | BM/PBSCs | CY ± ALG | CsA | CsA ± ALG | 878 (24–2750), 403 (NR); (Mean) (Day) | ***/**/** | 7 |
Viollier et al. (2005) [21] | 1976–1999 | Adult + Children | SAA + VSAA + NSAA | 19 (2–55), 23 (2–74) | 52/155 | MRD | BM/PBSCs | CY ± ATG | MTX, MTX + CsA | ATG, ATG + CsA | 11.5 (2–22), 11.3 (0.2–22); (Year) | ****/**/** | 8 |
Locasciulli et al. (2007) [22] | 1991–2002 | Adult + Children | SAA | 18.7 (1–67), 23.5 (1–94) | 1567/912 | MRD (85%) + MMRD (3%) + MUD (10%) | BM | Cy, Cy + ALG, Cy + Irradiation (TBI, TLI, TAI) | CsA ± MTX, some not specified | ALG + CsA ± G-CSF | 41 (24–155), 54.4 (14–144); (For alive) (Month) | ***/**/** | 7 |
George et al. (2015) [23] | 1985–2013 | Adult + Children | SAA + VSAA + NSAA | 22 (3–57), 30.1 (1.5–74) | 214/530 | MRD + MMRD (Percentage NR) | BM/PBSCs | Flu + Cy, Cy ± ATG, Flu + Bu and others | MTX + CsA, PT-CY | ATG/ALG + CsA | 36 (6–197), 38 (1–84); (Month) | ****/**/** | 8 |